发明授权
US07175847B1 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
有权
用不会抑制CD80与CTLA-4结合的抗CD80抗体治疗肠道炎症
- 专利标题： Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
- 专利标题（中）： 用不会抑制CD80与CTLA-4结合的抗CD80抗体治疗肠道炎症
-
申请号： US09576424申请日： 2000-05-22
-
公开(公告)号： US07175847B1公开(公告)日： 2007-02-13
- 发明人: Darrell R. Anderson , Nabil Hanna , Peter Brams
- 申请人： Darrell R. Anderson , Nabil Hanna , Peter Brams
- 申请人地址： US MA Cambridge
- 专利权人： Biogen Idec Inc.
- 当前专利权人： Biogen Idec Inc.
- 当前专利权人地址： US MA Cambridge
- 代理机构： Pillsbury Winthrop Shaw Pittman, LLP
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; C07K16/28
摘要：
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies, or B7.1-binding fragments thereof, may be used for the treatment of Crohn's disease.
信息查询
